TLX Telix Pharmaceuticals Ltd
- 18.610
- +0.130+0.70%
Telix Pharmaceuticals Ltd News
Markets Today: Wall Street Mixed, ASX Set so Slide
Telix Wins Fast Track Status From US FDA for New Brain Cancer PET Scan Imaging Agent
Telix Applies to FDA For Approval of Brain-Tumor Imaging Agent
Telix Shares Extend Gains Amid 'Evolving' Leadership Changes
Press Release: Telix Announces Reorganisation to Deliver on Strategic Priorities
Wilsons Keeps Their Buy Rating on Telix Pharmaceuticals Ltd. (TLPPF)
Bell Potter Downgrades Telix Pharmaceuticals to Hold From Buy; Price Target Is AU$21.30
Analysts Conflicted on These Healthcare Names: Alcon (ALC) and Telix Pharmaceuticals Ltd. (OtherTLPPF)
Telix Pharmaceuticals Price Target Raised 1.3% to A$32.30/Share by Jefferies
Telix Share Price Sinks 9% Despite Stellar Half-year Growth
Markets Today: Wall Street Slides Ahead of Jerome Powell Speech, ASX Set to Slip
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
Telix Pharmaceuticals Turns to H1 Profit as Revenue Jumps 65%
Telix Pharmaceuticals Says Won't Pay an Interim Dividend
Telix Pharmaceuticals Ltd: Telix 1H 2024 Results Presentation
Telix Pharmaceuticals Ltd: Telix 1H 2024 Results Release
Telix Pharmaceuticals Ltd: Telix 1H 2024 Appendix 4D and Interim Report
Cochlear Limited (CHEOF) Gets a Hold From Jarden
Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals Ltd. (OtherTLPPF), CSL (OtherCMXHF) and Neuren Pharmaceuticals Limited (OtherNURPF)
Telix Pharmaceuticals Target Price Cut 5.8% to A$21.30/Share by Bell Potter>TLX.AU
Analysis
Price Target
No Data
